Annual report [Section 13 and 15(d), not S-K Item 405]

Consolidated Statements of Operations

v3.25.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Net Revenue $ 9,362,022 $ 2,532,499
Operating expenses:    
Direct costs and expenses 5,983,475 1,740,884
Research and development 1,461,227 1,467,936
Clinical development 321,655 256,661
Selling, general and administrative 9,943,473 6,790,654
Depreciation and amortization 605,637 249,592
Total operating expenses 18,315,467 10,505,727
Loss from operations (8,953,445) (7,973,228)
Other income (expense):    
Interest income 17,610 122,131
Interest expense (92,475) (37,125)
Other income 10,323 3,325
Other expense (10,194) (31,121)
Loss before income taxes (9,028,181) (7,916,018)
Income tax expense (11,650) (20,993)
Net loss $ (9,039,831) $ (7,937,011)
Net loss per common share, basic $ (0.75) $ (0.91)
Net loss per common share, diluted $ (0.75) $ (0.91)
Weighted average common shares outstanding, basic 12,125,029 8,747,509
Weighted average common shares outstanding, diluted 12,125,029 8,747,509